407 related articles for article (PubMed ID: 33029628)
1. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.
DiNatale RG; Hakimi AA; Chan TA
Hum Mol Genet; 2020 Oct; 29(R2):R214-R225. PubMed ID: 33029628
[TBL] [Abstract][Full Text] [Related]
2. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
3. Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies.
Augustin RC; Cai WL; Luke JJ; Bao R
Clin Cancer Res; 2024 May; 30(9):1724-1732. PubMed ID: 38236069
[TBL] [Abstract][Full Text] [Related]
4. Predicting immunotherapy response through genomics.
Cormedi MCV; Van Allen EM; Colli LM
Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238
[TBL] [Abstract][Full Text] [Related]
5. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
6. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
Weng CY; Kao CX; Chang TS; Huang YH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
[TBL] [Abstract][Full Text] [Related]
7. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
8. Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
Mukherjee S
Cancer Biother Radiopharm; 2019 Oct; 34(8):487-497. PubMed ID: 31314580
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors in Geriatric Oncology.
Cook SL; Al Amin M; Bari S; Poonnen PJ; Khasraw M; Johnson MO
Curr Oncol Rep; 2024 May; 26(5):562-572. PubMed ID: 38587598
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
11. [Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].
Guo R; Li X; Hao M; Liang Y; Wang L; Yang Z
Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1403-1424. PubMed ID: 37154314
[TBL] [Abstract][Full Text] [Related]
12. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
13. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
[TBL] [Abstract][Full Text] [Related]
14. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
15. Frontiers in cancer immunotherapy-a symposium report.
Cable J; Greenbaum B; Pe'er D; Bollard CM; Bruni S; Griffin ME; Allison JP; Wu CJ; Subudhi SK; Mardis ER; Brentjens R; Sosman JA; Cemerski S; Zavitsanou AM; Proia T; Egeblad M; Nolan G; Goswami S; Spranger S; Mackall CL
Ann N Y Acad Sci; 2021 Apr; 1489(1):30-47. PubMed ID: 33184911
[TBL] [Abstract][Full Text] [Related]
16. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
17. Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies.
Kirchhoff T; Ferguson R
Methods Mol Biol; 2020; 2055():93-117. PubMed ID: 31502148
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
19. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]